Pfizer (NYSE:PFE) Trading Down 0.5%

Pfizer Inc. (NYSE:PFE)’s stock price traded down 0.5% during trading on Thursday . The company traded as low as $26.13 and last traded at $26.20. 8,393,610 shares were traded during mid-day trading, a decline of 80% from the average session volume of 42,477,508 shares. The stock had previously closed at $26.32.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the stock. Argus downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. TD Cowen downgraded shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price objective for the company. in a research note on Thursday, January 4th. Guggenheim initiated coverage on shares of Pfizer in a research note on Friday, February 23rd. They issued a “buy” rating and a $36.00 price objective for the company. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a research note on Monday, April 1st. Twelve investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $36.88.

Pfizer Trading Down 1.8 %

The company has a market capitalization of $146.49 billion, a PE ratio of 71.86, a price-to-earnings-growth ratio of 1.18 and a beta of 0.61. The company’s fifty day moving average is $27.28 and its 200-day moving average is $28.93. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.91 and a quick ratio of 0.69.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.29. The company had revenue of $14.25 billion for the quarter, compared to analyst estimates of $14.37 billion. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. Pfizer’s revenue was down 41.3% compared to the same quarter last year. During the same period last year, the company posted $1.14 earnings per share. On average, analysts anticipate that Pfizer Inc. will post 2.22 EPS for the current fiscal year.

Hedge Funds Weigh In On Pfizer

Institutional investors and hedge funds have recently bought and sold shares of the company. Fulton Bank N.A. grew its holdings in Pfizer by 4.7% in the third quarter. Fulton Bank N.A. now owns 176,239 shares of the biopharmaceutical company’s stock worth $5,846,000 after purchasing an additional 7,991 shares during the last quarter. Portside Wealth Group LLC purchased a new position in Pfizer in the second quarter worth $2,072,000. Adage Capital Partners GP L.L.C. grew its holdings in shares of Pfizer by 40.5% during the third quarter. Adage Capital Partners GP L.L.C. now owns 4,739,672 shares of the biopharmaceutical company’s stock valued at $157,215,000 after buying an additional 1,365,295 shares during the last quarter. Brookstone Capital Management grew its holdings in shares of Pfizer by 88.5% during the third quarter. Brookstone Capital Management now owns 452,352 shares of the biopharmaceutical company’s stock valued at $14,109,000 after buying an additional 212,369 shares during the last quarter. Finally, ETF Store Inc. grew its holdings in shares of Pfizer by 12.0% during the third quarter. ETF Store Inc. now owns 6,803 shares of the biopharmaceutical company’s stock valued at $214,000 after buying an additional 727 shares during the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.